{"doi":"10.1016/j.ijcchd.2022.100354","title":"Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease","abstract":"Background: Pulmonary hypertension (PH) due to left heart disease (World Health Organization (WHO) Group 2 PH) is the largest PH subgroup, however most reports of PH in pregnancy focus on patients with pulmonary arterial hypertension (WHO Group 1 PH). We evaluated pregnancy outcomes across WHO PH subgroups. Methods: We performed a retrospective single center cohort study of maternal and fetal outcomes in pregnant women with PH (2004-2018). Results: We analyzed outcomes of 70 pregnancies in 70 women with PH (30 ± 6 years-old), classified as WHO Group 1 PH (12 (17%)), Group 2 PH (45 (64%)), Group 3 PH (4 (6%)) and Group 5 PH (9 (13%)). Although no peripartum death occurred, 3 (4.3%) women with WHO Group 2 PH had late mortality (7 ± 4 months post- partum). Additionally, 33 major adverse cardiac events occurred in 26 (37%) women, preterm birth occurred in 32 (49%), and post-partum hemorrhage in 10 (14%), such that only 24 (37%) women completed a viable pregnancy free of an adverse cardiac, obstetric or fetal/neonatal event. Major adverse cardiac events were predominantly due to heart failure (24 (73%)), occurring only in WHO Groups 1 and 2 PH (3 (25%) women vs. 17 (38%), p = 0.07), and significantly associated with pre-eclampsia, left ventricular ejection fraction ≤45%, maternal diabetes, and systemic hypertension. Conclusions: WHO Group 2 PH carries similar risk for maternal cardiovascular events when compared to women with WHO Group 1 PH. Further studies evaluating maternal risk in this cohort are needed.","journal":"International Journal of Cardiology Congenital Heart Disease","year":2022,"id":289818,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9398,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":971419,"name":"Stephen E. Gee","orcid":"0000-0003-0561-4012","position":1,"is_corresponding":false},{"id":971420,"name":"Woobeen Lim","orcid":"0000-0002-4154-5133","position":2,"is_corresponding":false},{"id":386716,"name":"Lauren Lastinger","orcid":null,"position":3,"is_corresponding":false},{"id":640201,"name":"Michael Cackovic","orcid":"0000-0002-0256-5799","position":4,"is_corresponding":false},{"id":233344,"name":"Raymond L. Benza","orcid":"0000-0001-9627-6236","position":5,"is_corresponding":false},{"id":385848,"name":"Curt J. Daniels","orcid":"0000-0003-4201-6337","position":6,"is_corresponding":false},{"id":385845,"name":"Elisa A. Bradley","orcid":"0000-0003-1479-2988","position":7,"is_corresponding":false},{"id":385847,"name":"Saurabh Rajpal","orcid":"0000-0003-0772-8478","position":8,"is_corresponding":false},{"id":971418,"name":"William H. Marshall","orcid":"0000-0001-7350-6991","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:30:22.686776Z","pmid":"37435574","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}